Physician profile
Jon Jarvis
NPI 1225524812
$1,096.52
in general payments reported to CMS, 2019-2025
20 companies · $451 in 2025
The $451 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $38.53 · 2022: $167 · 2023: $80.63 · 2024: $359 · 2025: $451.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $891.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $890.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $230.71 | 2022-2025 | |
| Glaxosmithkline, LLC. | $209.35 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Corium, LLC | $99.70 | 2024-2025 | Azstarys |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $80.82 | 2025 | Caplyta |
| Lilly USA, LLC | $60.70 | 2022-2024 | Mounjaro, Zepbound |
| Otsuka America Pharmaceutical, INC. | $60.34 | 2025 | Rexulti |
| Ironshore Pharmaceuticals INC. | $58.79 | 2022-2024 | |
| Novo Nordisk INC | $51.92 | 2024-2025 | Rybelsus, Ozempic |
| Vanda Pharmaceuticals INC. | $46.37 | 2022-2025 | Fanapt |
| Abiomed | $25.26 | 2024 | Impella |
| Amgen INC. | $20.72 | 2025 | Otezla, Repatha |
| Phathom Pharmaceuticals, INC. | $18.76 | 2024 | Voquezna |
| Lundbeck LLC | $18.61 | 2025 | Rexulti |
| Cipher Pharmaceuticals US LLC | $17.94 | 2025 | Natroba, Spinosad |
| Biomarin Pharmaceutical INC. | $17.75 | 2024 | Palynziq |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $17.22 | 2024 | Crysvita |
| Exact Sciences Corporation | $16.98 | 2025 | Cologuard Collection Kit |
| Collegium Pharmaceutical, INC. | $16.06 | 2025 | Jornay Pm |
| Amarin Pharma, INC. | $14.87 | 2021 | |
| Insulet Corporation | $13.65 | 2025 | Omnipod |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jon Jarvis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.